MAPT and Alzheimer disease: In secondary prevention, therapeutic interventions involve drugs targeting Aβ and Tau pathology, or neuroinflammation; AD patients at this stage present with the main hallmarks of AD, such as Aβ and tau aggregates or neuroinflammation, even though cognitive function is retained [6,62,63,64,65].